{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:30:52Z","timestamp":1761514252109,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.yebeh.2018.08.004","type":"journal-article","created":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T01:18:28Z","timestamp":1534555108000},"page":"92-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Frequency of drug combinations between enzyme-inducing first-generation antiepileptic drugs and inducible drugs in patients with epilepsy"],"prefix":"10.1016","volume":"87","author":[{"given":"Gaetano","family":"Zaccara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Gualdani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Policardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Francesconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2018.08.004_bb0005","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/j.1875-9114.1998.tb03942.x","article-title":"Frequency of hospitalization after exposure to known drug\u2013drug interactions in a Medicaid population","volume":"18","author":"Hamilton","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/00002018-199309010-00005","article-title":"Epidemiology of drug\u2013drug interactions as a cause of hospital admissions","volume":"9","author":"Jankel","year":"1993","journal-title":"Drug Saf"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0015","first-page":"266","article-title":"Drug\u2013drug interactions associated with length of stay and cost of hospitalization","volume":"12","author":"Moura","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2165\/00002512-200825020-00006","article-title":"Increasing exposure to drug\u2013drug interactions between 1992 and 2005 in people aged \u226555\u202fyears","volume":"2","author":"Becker","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0025","doi-asserted-by":"crossref","first-page":"344","DOI":"10.18433\/J37K5W","article-title":"Prevalence and predictors of potential drug\u2013drug interactions in the elderly: a cross-sectional study in the Brazilian primary public health system","volume":"15","author":"Obreli Neto","year":"2012","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0030","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.sapharm.2015.09.004","article-title":"Identifying high risk medications causing potential drug\u2013drug interactions in outpatients: a prescription database study based on an online surveillance system","volume":"12","author":"Toivo","year":"2016","journal-title":"Res Social Adm Pharm"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: cause for concern?","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0040","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1684\/epd.2014.0714","article-title":"Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs","volume":"16","author":"Zaccara","year":"2014","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0045","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","article-title":"Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0050","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/epi.14010","article-title":"Risk of pharmacokinetic interactions between antiepileptic and other drugs in older persons and factors associated with risk","volume":"59","author":"Faught","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0060","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1212\/WNL.0000000000003629","article-title":"Prevalence of epilepsy\/seizures as a comorbidity of neurologic disorders in nursing homes","volume":"88","author":"Birnbaum","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0065","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1528-1167.2012.03528.x","article-title":"The somatic comorbidity of epilepsy: a weighty but often unrecognized burden","volume":"53","author":"Gaitatzis","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0070","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10072-016-2798-0","article-title":"Identification of prevalent patients with epilepsy using administrative data: the Tuscany experience","volume":"38","author":"Bellini","year":"2017","journal-title":"Neurol Sci"},{"author":"Medscape","key":"10.1016\/j.yebeh.2018.08.004_bb0075"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0080","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40262-013-0088-z","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs)\u2013part 2: pharmacokinetic and pharmacodynamics interactions between AEDs and drugs used to treat non-epilepsy disorders","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0085","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/157015910792246254","article-title":"Antiepileptic drug interactions \u2014 principles and clinical implications","volume":"8","author":"Johannessen","year":"2010","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0090","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1468-1331.2007.01970.x","article-title":"Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000\u20132005","volume":"14","author":"Savica","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0095","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/01.wnl.0000341789.77291.8d","article-title":"Assessment of potential drug interactions in patients with epilepsy: impact of age and sex","volume":"72","author":"Gidal","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0100","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"ILAE Subcommission on AED Guidelines updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0105","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1474-4422(03)00435-6","article-title":"Interactions between antiepileptic and chemotherapeutic drugs","volume":"2","author":"Vecht","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0110","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1528-1167.2011.03335.x","volume":"53","author":"Birbeck","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0115","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.0013-9580.2004.17504.x","article-title":"The epidemiology of the comorbidity of epilepsy in the general population","volume":"45","author":"Gaitatzis","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.08.004_bb0120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S1474-4422(15)00352-X","article-title":"Comorbidity as an epidemiological construct","volume":"15","author":"Keezer","year":"2016","journal-title":"Lancet Neurol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505018305821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505018305821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:27:53Z","timestamp":1761503273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505018305821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":23,"alternative-id":["S1525505018305821"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2018.08.004","relation":{},"ISSN":["1525-5050"],"issn-type":[{"type":"print","value":"1525-5050"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequency of drug combinations between enzyme-inducing first-generation antiepileptic drugs and inducible drugs in patients with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2018.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}